Mary‐Margaret Keating

Oral decitabine–cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): a registrational, randomised, crossover, pharmacokinetics, phase 3 study

Guillermo Garcia‐Manero, James McCloskey, Elizabeth A. Griffiths et al. · The Lancet Haematology · 2023 · 85 citations

Medicine, Pharmacokinetics, Pharmacology +13

Overall survival in lower <scp>IPSS</scp> risk <scp>MDS</scp> by receipt of iron chelation therapy, adjusting for patient‐related factors and measuring from time of first red blood cell transfusion dependence: an <scp>MDS</scp>‐<scp>CAN</scp> analysis

Heather A. Leitch, Ambica Parmar, Richard A. Wells et al. · British Journal of Haematology · 2017 · 64 citations · Full text

Medicine, Hematology, Iron Metabolism Disorders +13

Pharmacokinetic Exposure Equivalence and Preliminary Efficacy and Safety from a Randomized Cross over Phase 3 Study (ASCERTAIN study) of an Oral Hypomethylating Agent ASTX727 (cedazuridine/decitabine) Compared to IV Decitabine

Guillermo Garcia‐Manero, James McCloskey, Elizabeth A. Griffiths et al. · Blood · 2019 · 60 citations

Pharmacy, Pharmacokinetics, Pharmacology +13

Odronextamab monotherapy in patients with relapsed/refractory diffuse large B cell lymphoma: primary efficacy and safety analysis in phase 2 ELM-2 trial

Won Seog Kim, Tae Min Kim, Seok‐Goo Cho et al. · Nature Cancer · 2025 · 44 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Ibrutinib plus venetoclax in relapsed or refractory mantle cell lymphoma (SYMPATICO): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study

Michael Wang, Wojciech Jurczak, Marek Trněný et al. · The Lancet Oncology · 2025 · 38 citations · Full text

Medicine, Oncology, Pharmacology +12